Hurlstone David P, Hunter Michael D, Sanders David S, Thomson Mike, Cross Simon S
Gastroenterology and Liver Unit at the Royal Hallamshire Hospital, Sheffield, South Yorkshire, UK.
J Clin Gastroenterol. 2007 Feb;41(2):178-84. doi: 10.1097/01.mcg.0000225679.06971.bb.
Flat and depressed neoplastic lesions of the colorectum [Paris type (PT) 0-II] localized to the superficial submucosal (sm) layer can be managed using endoscopic mucosal resection. Successful endoluminal management can be enhanced using endoscopic or ultrasound tools that help predict the degree of sm invasion. Previous studies addressing invasive depth estimation using high-magnification chromoscopic colonoscopy showed a low specificity for deep sm layer 3 invasion with miniprobe ultrasound demonstrating better nodal and T stage in vivo prediction. High-resolution vascular mapping of lesions can show microvascular superficial changes that may predict sm invasive disease.
Vascular mapping in combination with high-magnification chromoscopic colonoscopy (HMCC) may provide an accurate tool for the invasive depth estimation of PT type II neoplastic lesions as compared with high frequency 20/12.5 MHz miniprobe ultrasound.
Sixty-eight patients with a known diagnosis of PT II neoplasia were imaged using 3 "back to back" imaging modalities. Phase 1-vascular ectasia mapping; phase 2-HMCC with crypt analysis according to Nagata criteria; phase 3-12.5/20 MHz miniprobe ultrasound. Lesions predicted as T0/1/N0 were resected using endoscopic mucosal resection with the remaining referred for surgery. Each imaging modality was then compared with the resected histopathologic specimen used as the "gold standard."
N=68 lesions (19 sm1/13 sm2/36 sm3). Overall accuracy of Nagata criteria, Nagata criteria combined with vascular mapping, and ultrasound staging was 65%, 78%, and 94%, respectively (P<0.001) when observing the between phase differences. Fifty-two lesions were resected surgically. The prevalence of node positive disease was 16% (8/52) with the remaining 44/52 (84%) being confirmed pN0 at histopathology. The kappa coefficient of agreement between invasive depth estimation (using histopathology as the gold standard), Nagata stage, Nagata stage plus vascular ectasia mapping and ultrasound stage was 0.47, 0.65, and 0.9, respectively. A significant improvement in between phase differences was observed (P=0.001).
This is the first study to address the in vivo clinical utility of vascular mapping in combination with HMCC for the T and N staging of PT II neoplasia. Combination imaging may provide an adequate clinical tool for both T and N stage assessment in vivo and help stratify those patients at high risk for T2/N1 disease that may benefit from further high-frequency miniprobe ultrasound (HFUS) assessment and possible primary surgical excision. This is important in the clinical context, given the high overall costs of a second HFUS examination, limitation of HFUS resources, and safe selection of patients undergoing primary endoscopic resection versus surgical resection.
局限于浅表黏膜下层(sm)的结直肠癌扁平及凹陷性肿瘤性病变[巴黎分型(PT)0-II型]可通过内镜黏膜切除术进行治疗。使用有助于预测sm层浸润程度的内镜或超声工具可提高腔内治疗的成功率。以往使用高倍放大染色结肠镜检查评估浸润深度的研究显示,对于深层sm3层浸润的特异性较低,而微型探头超声在体内对淋巴结和T分期的预测效果更好。病变的高分辨率血管成像可显示微血管的浅表变化,这可能预测sm浸润性疾病。
与高频20/12.5MHz微型探头超声相比,血管成像联合高倍放大染色结肠镜检查(HMCC)可能为PT II型肿瘤性病变的浸润深度评估提供一种准确的工具。
对68例已确诊为PT II型肿瘤形成的患者使用3种“背靠背”成像方式进行检查。第一阶段——血管扩张成像;第二阶段——根据永田标准进行隐窝分析的HMCC;第三阶段——12.5/20MHz微型探头超声检查。预测为T0/1/N0的病变采用内镜黏膜切除术切除,其余患者转诊接受手术治疗。然后将每种成像方式与用作“金标准”的切除组织病理标本进行比较。
共68个病变(19个sm1/13个sm2/36个sm3)。观察各阶段差异时,永田标准、永田标准联合血管成像以及超声分期的总体准确率分别为65%、78%和94%(P<0.001)。52个病变接受了手术切除。淋巴结阳性疾病的发生率为16%(8/52),其余44/52(84%)在组织病理学检查中被确认为pN0。浸润深度评估(以组织病理学为金标准)、永田分期、永田分期加血管扩张成像以及超声分期之间的kappa一致性系数分别为0.47、0.65和0.9。各阶段差异有显著改善(P=0.001)。
这是第一项探讨血管成像联合HMCC在PT II型肿瘤形成的T和N分期中的体内临床应用的研究。联合成像可能为体内T和N分期评估提供一种合适的临床工具,并有助于对那些可能从进一步的高频微型探头超声(HFUS)评估及可能的一期手术切除中获益的T2/N1疾病高危患者进行分层。鉴于第二次HFUS检查的总体成本较高、HFUS资源有限以及安全选择接受一期内镜切除与手术切除的患者,这在临床背景下具有重要意义。